Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2004

View Archived Issues

Cosmetic improvements induced by the Isolagen Process in the treatment of facial wrinkles and scars

LyphoDerm reported more effective than standard of care in venous leg ulcers

Significant antihypertensive effects reported for omapatrilat in the OCTAVE trial

ThromboGenics and Geymonat to codevelop placental growth factor

Pivotal trial planned for pixantrone for relapsed, aggressive NHL

BMS Medical Imaging and Kereos to develop novel molecular imaging agents

Research phase for development of atherosclerosis therapeutic

Ipsen acquires Sterix

ICE inhibitor pralnacasan prevents dextran sulfate sodium-induced colitis in mice

Antiinflammatory effects of the PDE4 inhibitor AWD-12-281 shown in human cell preparations

N-Myristoyltransferase inhibitors: Potential anticancer agents

SBIR grant supports development of GelVac intranasal vaccine delivery platform

Completion of patient enrollment announced for a trial on I2S in Hunter syndrome

New PARP inhibitors prepared and tested at Kyorin

Novel agents able to induce neural stem cell differentiation into neurons

New DPP-IV inhibitors developed by Yamanouchi scientists

Novel calpain inhibitors and their use in stroke, ocular disorders, etc. reported by Senju

New antiandrogenic agents in early development at Yamanouchi

Janssen claims new quinoline-based antimycobacterial agents

Two series of PPARalpha agonists presented by Merck scientists

Seikagaku patent covers GalNAc4S6ST inhibitors and their use

IND clearance allows initiation of clinical studies for ARRY-142886

Additional phase III data in support of TTFC

Data reported from Viramidine phase II trial

Foradil Certihaler receives Swiss approval

Expansion of Sankyo/Tularik GPCR collaboration

Enrollment progresses in first phase III study for Oxytrex

Enrollment under way in phase II trial of Aurexis

Cloretazine receives fast track status for AML